Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAP PAC
NCT05949658Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sirolimus and everolimus in aging (2 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Dose Limited Toxicities at 3 years. Started May 2024; status: recruiting.
02
Drugs
sirolimuseverolimus
03
Conditions
aging
Beyond the preview
Go deeper on NCT05949658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949658.